Targeting CD137 has been shown to be effective in treatment of rheumatoid arthritis and may thus be effective in other diseases associated with increased expression of this co-stimulatory molecule, including COPD (25). The gene discussed is TNFRSF9; the disease is chronic obstructive pulmonary disease.